Novel nanoformulation of disulfiram with bacterially synthesized copper oxide nanoparticles for augmenting anticancer activity: an in vitro study View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-09-06

AUTHORS

Marwa M. Abu‑Serie, Marwa Eltarahony

ABSTRACT

BackgroundDisulfiram (DS), in the presence of copper (Cu), exhibited potent broad anticancer activity. However, its clinical application is limited due to the poor solubility and stability. Hence, a novel nanocombination of DS with bacterially synthesized copper oxide nanoparticles (CuO NPs) was prepared herein to improve the anticancer efficacy of the typical DS–Cu complex. Our design utilized the nanocharacterization and prooxidant effect-mediated anticancer activity of CuO NPs which may lead to enhanced cellular uptake and thus improved anticancer efficacy of this unique nanocomplex.ResultsThe characterized DS–CuO NPs exhibited high stability in serum and the strongest selective anticancer activity, with the lowest half-maximum inhibitory concentration (IC50 < 15 nM), against human breast, lung and liver cancer cells, by >10-fold, compared to DS–Cu, CuO NPs and Cu. Importantly, DS–CuO NPs revealed better synergistic anticancer effect and higher cellular uptake than DS–Cu. Moreover, this novel nanocomplex showed higher prooxidant effect-mediated apoptosis and anti-metastatic potential. This was accomplished by elevating cellular reactive species content with inhibiting the antioxidant defenders (functional marker of cancer stem cells (aldehyde dehydrogenase) and nuclear factor erythroid 2-related factor2), matrix metallopeptidase 9 and NF-κB as well as enhancing p53 expression.ConclusionAll of the aforementioned findings verified that this novel nanocomplex was capable of improving the therapeutic index of the conventional DS–Cu complex. The potent selective anticancer activity of this promising nanomedicine merits further investigation, as a separate future study, using animal models as preliminary step before its clinical application.Graphic abstract More... »

PAGES

25

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12645-021-00097-5

DOI

http://dx.doi.org/10.1186/s12645-021-00097-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1140919775


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Medical Biotechnology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), City of Scientific Research and Technological Applications (SRTA-City), 21934, New Borg El\u2011Arab City, Alexandria, Egypt", 
          "id": "http://www.grid.ac/institutes/grid.420020.4", 
          "name": [
            "Medical Biotechnology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), City of Scientific Research and Technological Applications (SRTA-City), 21934, New Borg El\u2011Arab City, Alexandria, Egypt"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Abu\u2011Serie", 
        "givenName": "Marwa M.", 
        "id": "sg:person.01232563730.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01232563730.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Environmental Biotechnology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), City of Scientific Research and Technological Applications (SRTA-City), 21934, New Borg El\u2011Arab City, Alexandria, Egypt", 
          "id": "http://www.grid.ac/institutes/grid.420020.4", 
          "name": [
            "Environmental Biotechnology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), City of Scientific Research and Technological Applications (SRTA-City), 21934, New Borg El\u2011Arab City, Alexandria, Egypt"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Eltarahony", 
        "givenName": "Marwa", 
        "id": "sg:person.016243533706.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016243533706.44"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/1477-3155-12-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031265962", 
          "https://doi.org/10.1186/1477-3155-12-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41598-021-87363-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1136991621", 
          "https://doi.org/10.1038/s41598-021-87363-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10529-017-2463-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092556456", 
          "https://doi.org/10.1007/s10529-017-2463-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2402417", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044065576", 
          "https://doi.org/10.1038/sj.leu.2402417"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11064-015-1688-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019091227", 
          "https://doi.org/10.1007/s11064-015-1688-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2012.442", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025902917", 
          "https://doi.org/10.1038/bjc.2012.442"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2021-09-06", 
    "datePublishedReg": "2021-09-06", 
    "description": "BackgroundDisulfiram (DS), in the presence of copper (Cu), exhibited potent broad anticancer activity. However, its clinical application is limited due to the poor solubility and stability. Hence, a novel nanocombination of DS with bacterially synthesized copper oxide nanoparticles (CuO NPs) was prepared herein to improve the anticancer efficacy of the typical DS\u2013Cu complex. Our design utilized the nanocharacterization and prooxidant effect-mediated anticancer activity of CuO NPs which may lead to enhanced cellular uptake and thus improved anticancer efficacy of this unique nanocomplex.ResultsThe characterized DS\u2013CuO NPs exhibited high stability in serum and the strongest selective anticancer activity, with the lowest half-maximum inhibitory concentration (IC50\u2009<\u200915\u00a0nM), against human breast, lung and liver cancer cells, by\u2009>10-fold, compared to DS\u2013Cu, CuO NPs and Cu. Importantly, DS\u2013CuO NPs revealed better synergistic anticancer effect and higher cellular uptake than DS\u2013Cu. Moreover, this novel nanocomplex showed higher prooxidant effect-mediated apoptosis and anti-metastatic potential. This was accomplished by elevating cellular reactive species content with inhibiting the antioxidant defenders (functional marker of cancer stem cells (aldehyde dehydrogenase) and nuclear factor erythroid 2-related factor2), matrix metallopeptidase 9 and NF-\u03baB as well as enhancing p53 expression.ConclusionAll of the aforementioned findings verified that this novel nanocomplex was capable of improving the therapeutic index of the conventional DS\u2013Cu complex. The potent selective anticancer activity of this promising nanomedicine merits further investigation, as a separate future study, using animal models as preliminary step before its clinical application.Graphic abstract", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12645-021-00097-5", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1042272", 
        "issn": [
          "1868-6958", 
          "1868-6966"
        ], 
        "name": "Cancer Nanotechnology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "12"
      }
    ], 
    "keywords": [
      "selective anticancer activity", 
      "anticancer activity", 
      "anti-metastatic potential", 
      "matrix metallopeptidase 9", 
      "anticancer efficacy", 
      "clinical application", 
      "half-maximum inhibitory concentration", 
      "broad anticancer activity", 
      "low half-maximum inhibitory concentration", 
      "liver cancer cells", 
      "synergistic anticancer effect", 
      "metallopeptidase 9", 
      "NF-\u03baB", 
      "therapeutic index", 
      "p53 expression", 
      "animal models", 
      "anticancer effects", 
      "cellular uptake", 
      "human breast", 
      "cancer cells", 
      "inhibitory concentration", 
      "novel nanoformulation", 
      "further investigation", 
      "higher cellular uptake", 
      "efficacy", 
      "future studies", 
      "promising nanomedicine", 
      "novel nanocomplex", 
      "lung", 
      "activity", 
      "breast", 
      "copper oxide nanoparticles", 
      "uptake", 
      "disulfiram", 
      "serum", 
      "ResultsThe", 
      "poor solubility", 
      "apoptosis", 
      "novel nanocombination", 
      "ConclusionAll", 
      "study", 
      "oxide nanoparticles", 
      "CuO NPs", 
      "cells", 
      "expression", 
      "nanoformulations", 
      "findings", 
      "nanocomplexes", 
      "presence of copper", 
      "index", 
      "DS", 
      "high stability", 
      "effect", 
      "presence", 
      "concentration", 
      "DS-Cu", 
      "nanomedicine", 
      "nanoparticles", 
      "species content", 
      "complexes", 
      "potential", 
      "investigation", 
      "NPs", 
      "preliminary step", 
      "stability", 
      "solubility", 
      "nanocharacterization", 
      "copper", 
      "Cu", 
      "content", 
      "model", 
      "applications", 
      "design", 
      "step", 
      "defenders"
    ], 
    "name": "Novel nanoformulation of disulfiram with bacterially synthesized copper oxide nanoparticles for augmenting anticancer activity: an in vitro study", 
    "pagination": "25", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1140919775"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12645-021-00097-5"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12645-021-00097-5", 
      "https://app.dimensions.ai/details/publication/pub.1140919775"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:39", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_919.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12645-021-00097-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12645-021-00097-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12645-021-00097-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12645-021-00097-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12645-021-00097-5'


 

This table displays all metadata directly associated to this object as RDF triples.

166 TRIPLES      22 PREDICATES      106 URIs      92 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12645-021-00097-5 schema:about anzsrc-for:11
2 anzsrc-for:1115
3 schema:author N57190132f6bd417d9043335454cf3432
4 schema:citation sg:pub.10.1007/s10529-017-2463-6
5 sg:pub.10.1007/s11064-015-1688-9
6 sg:pub.10.1038/bjc.2012.442
7 sg:pub.10.1038/s41598-021-87363-z
8 sg:pub.10.1038/sj.leu.2402417
9 sg:pub.10.1186/1477-3155-12-5
10 schema:datePublished 2021-09-06
11 schema:datePublishedReg 2021-09-06
12 schema:description BackgroundDisulfiram (DS), in the presence of copper (Cu), exhibited potent broad anticancer activity. However, its clinical application is limited due to the poor solubility and stability. Hence, a novel nanocombination of DS with bacterially synthesized copper oxide nanoparticles (CuO NPs) was prepared herein to improve the anticancer efficacy of the typical DS–Cu complex. Our design utilized the nanocharacterization and prooxidant effect-mediated anticancer activity of CuO NPs which may lead to enhanced cellular uptake and thus improved anticancer efficacy of this unique nanocomplex.ResultsThe characterized DS–CuO NPs exhibited high stability in serum and the strongest selective anticancer activity, with the lowest half-maximum inhibitory concentration (IC50 < 15 nM), against human breast, lung and liver cancer cells, by >10-fold, compared to DS–Cu, CuO NPs and Cu. Importantly, DS–CuO NPs revealed better synergistic anticancer effect and higher cellular uptake than DS–Cu. Moreover, this novel nanocomplex showed higher prooxidant effect-mediated apoptosis and anti-metastatic potential. This was accomplished by elevating cellular reactive species content with inhibiting the antioxidant defenders (functional marker of cancer stem cells (aldehyde dehydrogenase) and nuclear factor erythroid 2-related factor2), matrix metallopeptidase 9 and NF-κB as well as enhancing p53 expression.ConclusionAll of the aforementioned findings verified that this novel nanocomplex was capable of improving the therapeutic index of the conventional DS–Cu complex. The potent selective anticancer activity of this promising nanomedicine merits further investigation, as a separate future study, using animal models as preliminary step before its clinical application.Graphic abstract
13 schema:genre article
14 schema:inLanguage en
15 schema:isAccessibleForFree true
16 schema:isPartOf N556300cd3eb5438fb19d64cec2025ec9
17 Ncb635fb6134141709e8d5c52970e7874
18 sg:journal.1042272
19 schema:keywords ConclusionAll
20 Cu
21 CuO NPs
22 DS
23 DS-Cu
24 NF-κB
25 NPs
26 ResultsThe
27 activity
28 animal models
29 anti-metastatic potential
30 anticancer activity
31 anticancer effects
32 anticancer efficacy
33 apoptosis
34 applications
35 breast
36 broad anticancer activity
37 cancer cells
38 cells
39 cellular uptake
40 clinical application
41 complexes
42 concentration
43 content
44 copper
45 copper oxide nanoparticles
46 defenders
47 design
48 disulfiram
49 effect
50 efficacy
51 expression
52 findings
53 further investigation
54 future studies
55 half-maximum inhibitory concentration
56 high stability
57 higher cellular uptake
58 human breast
59 index
60 inhibitory concentration
61 investigation
62 liver cancer cells
63 low half-maximum inhibitory concentration
64 lung
65 matrix metallopeptidase 9
66 metallopeptidase 9
67 model
68 nanocharacterization
69 nanocomplexes
70 nanoformulations
71 nanomedicine
72 nanoparticles
73 novel nanocombination
74 novel nanocomplex
75 novel nanoformulation
76 oxide nanoparticles
77 p53 expression
78 poor solubility
79 potential
80 preliminary step
81 presence
82 presence of copper
83 promising nanomedicine
84 selective anticancer activity
85 serum
86 solubility
87 species content
88 stability
89 step
90 study
91 synergistic anticancer effect
92 therapeutic index
93 uptake
94 schema:name Novel nanoformulation of disulfiram with bacterially synthesized copper oxide nanoparticles for augmenting anticancer activity: an in vitro study
95 schema:pagination 25
96 schema:productId N79d3b702eb0c4671847f86b760c93d0b
97 Nfadeef725c1a4cb787b9eb0b2a9e9dea
98 schema:sameAs https://app.dimensions.ai/details/publication/pub.1140919775
99 https://doi.org/10.1186/s12645-021-00097-5
100 schema:sdDatePublished 2022-05-20T07:39
101 schema:sdLicense https://scigraph.springernature.com/explorer/license/
102 schema:sdPublisher Nffa00bed541d454e92a22823344ca509
103 schema:url https://doi.org/10.1186/s12645-021-00097-5
104 sgo:license sg:explorer/license/
105 sgo:sdDataset articles
106 rdf:type schema:ScholarlyArticle
107 N556300cd3eb5438fb19d64cec2025ec9 schema:volumeNumber 12
108 rdf:type schema:PublicationVolume
109 N57190132f6bd417d9043335454cf3432 rdf:first sg:person.01232563730.11
110 rdf:rest Na0fccc09150043989396ea8818c085b2
111 N79d3b702eb0c4671847f86b760c93d0b schema:name dimensions_id
112 schema:value pub.1140919775
113 rdf:type schema:PropertyValue
114 Na0fccc09150043989396ea8818c085b2 rdf:first sg:person.016243533706.44
115 rdf:rest rdf:nil
116 Ncb635fb6134141709e8d5c52970e7874 schema:issueNumber 1
117 rdf:type schema:PublicationIssue
118 Nfadeef725c1a4cb787b9eb0b2a9e9dea schema:name doi
119 schema:value 10.1186/s12645-021-00097-5
120 rdf:type schema:PropertyValue
121 Nffa00bed541d454e92a22823344ca509 schema:name Springer Nature - SN SciGraph project
122 rdf:type schema:Organization
123 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
124 schema:name Medical and Health Sciences
125 rdf:type schema:DefinedTerm
126 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
127 schema:name Pharmacology and Pharmaceutical Sciences
128 rdf:type schema:DefinedTerm
129 sg:journal.1042272 schema:issn 1868-6958
130 1868-6966
131 schema:name Cancer Nanotechnology
132 schema:publisher Springer Nature
133 rdf:type schema:Periodical
134 sg:person.01232563730.11 schema:affiliation grid-institutes:grid.420020.4
135 schema:familyName Abu‑Serie
136 schema:givenName Marwa M.
137 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01232563730.11
138 rdf:type schema:Person
139 sg:person.016243533706.44 schema:affiliation grid-institutes:grid.420020.4
140 schema:familyName Eltarahony
141 schema:givenName Marwa
142 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016243533706.44
143 rdf:type schema:Person
144 sg:pub.10.1007/s10529-017-2463-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092556456
145 https://doi.org/10.1007/s10529-017-2463-6
146 rdf:type schema:CreativeWork
147 sg:pub.10.1007/s11064-015-1688-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019091227
148 https://doi.org/10.1007/s11064-015-1688-9
149 rdf:type schema:CreativeWork
150 sg:pub.10.1038/bjc.2012.442 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025902917
151 https://doi.org/10.1038/bjc.2012.442
152 rdf:type schema:CreativeWork
153 sg:pub.10.1038/s41598-021-87363-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1136991621
154 https://doi.org/10.1038/s41598-021-87363-z
155 rdf:type schema:CreativeWork
156 sg:pub.10.1038/sj.leu.2402417 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044065576
157 https://doi.org/10.1038/sj.leu.2402417
158 rdf:type schema:CreativeWork
159 sg:pub.10.1186/1477-3155-12-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031265962
160 https://doi.org/10.1186/1477-3155-12-5
161 rdf:type schema:CreativeWork
162 grid-institutes:grid.420020.4 schema:alternateName Environmental Biotechnology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), City of Scientific Research and Technological Applications (SRTA-City), 21934, New Borg El‑Arab City, Alexandria, Egypt
163 Medical Biotechnology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), City of Scientific Research and Technological Applications (SRTA-City), 21934, New Borg El‑Arab City, Alexandria, Egypt
164 schema:name Environmental Biotechnology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), City of Scientific Research and Technological Applications (SRTA-City), 21934, New Borg El‑Arab City, Alexandria, Egypt
165 Medical Biotechnology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), City of Scientific Research and Technological Applications (SRTA-City), 21934, New Borg El‑Arab City, Alexandria, Egypt
166 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...